• TRM (USD/COP)COP 3,461.92 +1.37% +COP 46.82Colombia's official exchange rate (Financial Superintendence), valid Nov 21 to Nov 23
  • EuroCOP 3,804.64 +1.37% +COP 51.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
  • Mexican pesoCOP 181.56 +1.37% +COP 2.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote

Anixa Biosciences secures Canadian patent for its ovarian cancer vaccine

FinanceInternationalTradingViewAI summary
Image: TradingView

Canada granted Anixa Biosciences patent 3,005,025, which covers aspects of its ovarian cancer vaccine technology. The protection complements a US patent granted in July 2025. The release, distributed by PR Newswire, does not include financial terms or clinical results for the vaccine.

In 25 seconds

  • Canada granted Anixa Biosciences patent 3,005,025 covering its ovarian cancer vaccine technology.
  • The patent complements protection from a US patent granted in July 2025.
  • The release does not include financial terms or clinical results for the vaccine.
Read the full story at TradingView

IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.

    Keep reading